Clinical Report: The Role of Trazodone in Managing Psychiatric Adverse Events Induced by ALK Inhibitors
Background
Lorlatinib, a third-generation tyrosine kinase inhibitor, is used for treating ALK-positive metastatic non-small cell lung cancer but is associated with psychiatric adverse events in approximately 60% of patients, according to clinical studies. Understanding and managing these adverse effects is crucial for improving patient outcomes and quality of life during treatment.
Data Highlights
Assessment
Score at T0
Score at T3
Score at T4
HAM-A (Anxiety)
27
6
6
ISI (Sleep Quality)
6
11
11
Key Findings
The patient developed psychiatric symptoms after 6 weeks of lorlatinib treatment.
Trazodone was administered at a dose of 75 mg/day, leading to improved sleep quality and reduced anxiety.
The HAM-A score decreased from 27 at baseline to 6 after treatment.
Initial psychiatric symptoms included affect lability and episodes of derealization.
Quality of life improved following the management of anxiety and insomnia.
Clinical Implications
Clinicians should be aware of the potential for psychiatric adverse events in patients treated with lorlatinib and consider early psychiatric intervention.
Conclusion
The case illustrates the importance of monitoring and addressing psychiatric symptoms in patients receiving lorlatinib.
